Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced topline results from the pivotal ...

The first gene-editing therapies for HIV/Aids are entering trials but the virus is proving once again that it is a master at ...

Merck reports positive results from phase 3 trial of once-daily, oral, two-drug, single-tablet regimen of Doravirine/Islatravir in treatment-naïve adults with HIV-1 infection ...

You can now be vaccinated against HIV – but that does not mean you can be reckless, warns the Department of Health ...

MSD announced the data just days after Gilead also touted success with a once-daily antiretroviral therapy (ART).

Gilead Sciences, Inc. is rated a Buy with robust profitability, solid dividend, prudent M&A and 15-20% upside potential. Read ...

WHO emphasizes integrating surveillance into national STI programs. Zoliflodacin, a novel antimicrobial agent, shows promise in treating gonorrhea, demonstrating non-inferiority to ...

A daily pill that is cheaper and easier to take than currently available weight loss drugs helps people lose around a tenth ...

SHELTON, CONNECTICUT / ACCESS Newswire / November 17, 2025 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the “Company”), reports that it has filed its Quarterly Report on Form 10-Q for the fiscal quarter ...

Short jail stays for minor crimes turn deadly when filth and a lack of care let infections run out of control, a USA TODAY ...

Either we get ahead of this crisis or watch a generation of Americans be swept into the devastating grip of disease.